Table 3 Clinical and histopathological prevalence parameters and DNA methylation pattern for RARB and RASSF1A genes in 49 fresh urinary bladder carcinoma tissues.
Variable | RARB | OR (95% CI) | RASSF1A | OR (95% CI) | ||
|---|---|---|---|---|---|---|
| Â | N(a) | P(a) | Â | N(a) | P(a) | Â |
Age # | Â | Â | Â | Â | Â | Â |
< 60 years | 1 | 8 | 1.0 (ref) | 6 | 3 | 1.0 (ref) |
≥ 60 years | 8 | 31 | 0.48 (0.05–4.45) | 31 | 8 | 0.51 (0.10–2.52) |
Sex* | Â | Â | Â | Â | Â | Â |
Female | 3 | 6 | 1.0 (ref) | 9 | 0 | na p (1) = 0,097 |
Male | 6 | 34 | 2.83 (0.55–14.54) | 29 | 11 |  |
Growth pattern* (b) | ||||||
Non-papillary | 2 | 7 | 1.0 (ref) | 12 | 4 | 1.0 (ref) |
Papillary | 14 | 26 | 0.53 (0.09–2.90) | 26 | 7 | 0.80 (0.19–3.29) |
Differentiation grade* (b) | ||||||
Low | 5 | 16 | 1.0 (ref) | 18 | 3 | 1.0 (ref) |
High | 4 | 24 | 1.88 (0.44–8.07) | 20 | 8 | 2.40 (0.55–10.46) |
Muscle invasion* (b) | ||||||
Noninvasive | 7 | 23 | 1.0 (ref) | 24 | 6 | 1.0 (ref) |
Invasive | 2 | 17 | 2.59 (0.48–14.05) | 14 | 5 | 1.43 (0.37–5.55) |
Post-surgery recurrence* | ||||||
Absence | 4(0/20) | 22(4/20) | 1.0 (ref) | 19(3/20) | 7(1/20) | 1.0 (ref) |
Presence | 5(1/20) | 18(15/20) | 0.65 (0.15–2.80) | 19(13/20) | 4(3/20) | 0.57 (0.14–2.27) |